An Open-Label Study of Two Formulations of LX1033 in Healthy Human Subjects

NCT01411800 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Irritable Bowel Syndrome

Interventions

DRUG: 250 mg capsule
DRUG: 250 mg tablets

Sponsor

Lexicon Pharmaceuticals